Qiagen (NYSE:QGEN) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Qiagen (NYSE:QGEN) have earned an average rating of “Moderate Buy” from the ten brokerages that are currently covering the stock, MarketBeat reports. Four research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 12-month target price among analysts that have covered the stock in the last year is $50.88.

QGEN has been the topic of a number of research analyst reports. HSBC downgraded Qiagen from a “buy” rating to a “hold” rating and set a $49.00 price target on the stock. in a report on Thursday, October 17th. Hsbc Global Res upgraded Qiagen to a “hold” rating in a report on Thursday, October 17th. Finally, Robert W. Baird boosted their price target on Qiagen from $49.00 to $52.00 and gave the company an “outperform” rating in a report on Friday, August 2nd.

Qiagen Trading Down 0.4 %

NYSE QGEN opened at $40.81 on Wednesday. Qiagen has a 1-year low of $39.03 and a 1-year high of $47.44. The company has a current ratio of 2.17, a quick ratio of 1.89 and a debt-to-equity ratio of 0.39. The stock has a 50-day moving average of $43.65 and a 200-day moving average of $43.74. The firm has a market cap of $9.31 billion, a PE ratio of 104.64, a price-to-earnings-growth ratio of 3.14 and a beta of 0.41.

Hedge Funds Weigh In On Qiagen

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. TD Asset Management Inc bought a new position in Qiagen in the 2nd quarter valued at approximately $2,103,000. Raymond James & Associates lifted its position in Qiagen by 12.7% in the 2nd quarter. Raymond James & Associates now owns 542,453 shares of the company’s stock valued at $22,289,000 after acquiring an additional 61,008 shares in the last quarter. Barings LLC bought a new position in Qiagen in the 2nd quarter valued at approximately $12,463,000. Sei Investments Co. lifted its position in Qiagen by 19.7% in the 2nd quarter. Sei Investments Co. now owns 1,696,319 shares of the company’s stock valued at $69,702,000 after acquiring an additional 278,930 shares in the last quarter. Finally, Sycomore Asset Management bought a new position in shares of Qiagen during the 2nd quarter valued at $4,425,000. 70.00% of the stock is owned by institutional investors.

Qiagen Company Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.